Vtv Theraptcs Cl A (VTVT)

$33.35 -0.15 (-0.45%)
Market Cap 131.95M
Revenue (ttm) 0.00
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,300
Avg Vol 52,010
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 20%
Beta 0.26
Analysts Strong Sell
Price Target $53.00

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology
Sector: Healthcare
Phone: 336 841 0300
Fax: 336 841 0310
Address:
3980 Premier Drive, Suite 310, High Point, United States
GDS_investing
GDS_investing May. 29 at 4:08 PM
$SPCE looking great and strong breakout mode we need to corss 5.23 next fast target 6.64 and 8.19 a lot of room to run here REVERSAL MODE long $SPCE $VTVT $RFL
1 · Reply
dcajic2
dcajic2 May. 29 at 2:57 PM
$VTVT potential is there but any readings are not for many many months. I still like the stock under $30
0 · Reply
GDS_investing
GDS_investing May. 29 at 2:07 PM
$SPCE great call here glta my followers still long. now watch $VTVT very low float Huge potential Read all my posts about her. long $VTVT
0 · Reply
dcajic2
dcajic2 May. 29 at 1:44 PM
$VTVT not sure what makes it bullish yet. Yes if their data comes in strong in second half of the year then bullish but not just yet.
0 · Reply
GDS_investing
GDS_investing May. 28 at 2:56 PM
$ZIM $35 or $37.5 buyout offers now only 24.80 !! Long and Strong $VTVT
0 · Reply
dcajic2
dcajic2 May. 28 at 1:53 PM
$VTVT shorts still working out. Still likely many many nights before any real news. The news may be good but it might not be.
0 · Reply
GDS_investing
GDS_investing May. 27 at 3:45 PM
$VTVT 100% upside LONG
0 · Reply
GDS_investing
GDS_investing May. 27 at 3:39 PM
$VTVT BUY RATING $67 PRICE TARGET
0 · Reply
dcajic2
dcajic2 May. 26 at 6:30 PM
$VTVT short is working out. Too early to be long
0 · Reply
dcajic2
dcajic2 May. 26 at 2:13 PM
$VTVT looking for a few more shorts. Still many many weeks away from any news. Not sure who is buying when management doesn’t keep shareholders in the loop of what actually is going on.
0 · Reply
Latest News on VTVT
vTv Therapeutics reports Q1 EPS $1.65, consensus 21c

2026-05-13T20:13:15.000Z - 16 days ago

vTv Therapeutics reports Q1 EPS $1.65, consensus 21c

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 4:01 PM EDT - 16 days ago

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026, 4:15 PM EDT - 21 days ago

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2026, 8:00 AM EDT - 23 days ago

vTv Therapeutics to Participate in Upcoming May Investor Conferences

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

Mar 16, 2026, 8:00 AM EDT - 2 months ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

vTv Therapeutics initiated with an Outperform at Evercore ISI

2026-03-12T10:46:05.000Z - 2 months ago

vTv Therapeutics initiated with an Outperform at Evercore ISI

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

2026-03-11T11:11:56.000Z - 2 months ago

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

2026-03-10T20:11:02.000Z - 2 months ago

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 4:01 PM EDT - 2 months ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

vTv Therapeutics to Participate in Upcoming Investor Conferences

Feb 13, 2026, 8:00 AM EST - 3 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics expanded its license agreement with Newsoara Biopharma

2026-02-02T13:15:17.000Z - 4 months ago

vTv Therapeutics expanded its license agreement with Newsoara Biopharma

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Feb 2, 2026, 8:00 AM EST - 4 months ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

vTv Therapeutics price target raised to $49 from $40 at BTIG

2026-01-27T12:25:32.000Z - 4 months ago

vTv Therapeutics price target raised to $49 from $40 at BTIG

vTv Therapeutics initiated with a Buy at Roth Capital

2026-01-22T21:11:50.000Z - 4 months ago

vTv Therapeutics initiated with a Buy at Roth Capital

vTv Therapeutics initiated with a Buy at TD Cowen

2026-01-05T10:50:07.000Z - 5 months ago

vTv Therapeutics initiated with a Buy at TD Cowen

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

2025-12-19T13:20:18.000Z - 5 months ago

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi

2025-12-18T21:10:54.000Z - 5 months ago

vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Dec 18, 2025, 4:05 PM EST - 5 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

vTv Therapeutics initiated with a Buy at BTIG

2025-11-18T21:20:58.000Z - 6 months ago

vTv Therapeutics initiated with a Buy at BTIG

vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)

2025-11-06T22:30:59.000Z - 7 months ago

vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:15 PM EST - 7 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics trading resumes

2025-11-05T14:42:37.000Z - 7 months ago

vTv Therapeutics trading resumes

vTv Therapeutics trading halted, volatility trading pause

2025-11-05T14:36:57.000Z - 7 months ago

vTv Therapeutics trading halted, volatility trading pause

vTv Therapeutics announces three appointments to Scientific Advisory Board

2025-10-09T12:11:55.000Z - 8 months ago

vTv Therapeutics announces three appointments to Scientific Advisory Board

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders

2025-10-03T20:45:20.000Z - 8 months ago

vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders

vTv Therapeutics trading resumes

2025-09-17T14:00:38.000Z - 9 months ago

vTv Therapeutics trading resumes

vTv Therapeutics trading halted, volatility trading pause

2025-09-17T13:55:25.000Z - 9 months ago

vTv Therapeutics trading halted, volatility trading pause

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 15, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 4:57 PM EDT - 9 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics announces $80M private placement

2025-09-02T12:30:44.000Z - 9 months ago

vTv Therapeutics announces $80M private placement

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Sep 2, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:15 PM EDT - 10 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin

2025-08-11T12:20:35.000Z - 10 months ago

vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 11, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Aug 7, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025, 9:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 1 year ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025, 12:00 PM EDT - 1 year ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jul 26, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Jun 24, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 28, 2024, 8:00 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2023, 4:30 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023, 8:33 AM EDT - 3 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

GDS_investing
GDS_investing May. 29 at 4:08 PM
$SPCE looking great and strong breakout mode we need to corss 5.23 next fast target 6.64 and 8.19 a lot of room to run here REVERSAL MODE long $SPCE $VTVT $RFL
1 · Reply
dcajic2
dcajic2 May. 29 at 2:57 PM
$VTVT potential is there but any readings are not for many many months. I still like the stock under $30
0 · Reply
GDS_investing
GDS_investing May. 29 at 2:07 PM
$SPCE great call here glta my followers still long. now watch $VTVT very low float Huge potential Read all my posts about her. long $VTVT
0 · Reply
dcajic2
dcajic2 May. 29 at 1:44 PM
$VTVT not sure what makes it bullish yet. Yes if their data comes in strong in second half of the year then bullish but not just yet.
0 · Reply
GDS_investing
GDS_investing May. 28 at 2:56 PM
$ZIM $35 or $37.5 buyout offers now only 24.80 !! Long and Strong $VTVT
0 · Reply
dcajic2
dcajic2 May. 28 at 1:53 PM
$VTVT shorts still working out. Still likely many many nights before any real news. The news may be good but it might not be.
0 · Reply
GDS_investing
GDS_investing May. 27 at 3:45 PM
$VTVT 100% upside LONG
0 · Reply
GDS_investing
GDS_investing May. 27 at 3:39 PM
$VTVT BUY RATING $67 PRICE TARGET
0 · Reply
dcajic2
dcajic2 May. 26 at 6:30 PM
$VTVT short is working out. Too early to be long
0 · Reply
dcajic2
dcajic2 May. 26 at 2:13 PM
$VTVT looking for a few more shorts. Still many many weeks away from any news. Not sure who is buying when management doesn’t keep shareholders in the loop of what actually is going on.
0 · Reply
GDS_investing
GDS_investing May. 22 at 2:14 PM
$VTVT looking great and strong for reversal mode need to corss 44 for fast run up LONG $VTVT
0 · Reply
GDS_investing
GDS_investing May. 22 at 2:11 PM
$VTVT vTv Therapeutics: Buy Rating Reiterated on Favorable Risk-Reward and Clinical Momentum; $67 Price Target !!! 91% UPSIDE here very low float volume is the we need to corss 44 run to 56$ my target here 84$ ! LONG and STRONG $VTVT watch $LFS $PCLA $QTEX $BIYA https://www.tipranks.com/news/ratings/vtv-therapeutics-buy-rating-reiterated-on-favorable-risk-reward-and-clinical-momentum-67-price-target-unchanged-ratings-news
0 · Reply
GDS_investing
GDS_investing May. 22 at 2:08 PM
$VTVT vTv Therapeutics: Buy Rating Reiterated on Favorable Risk-Reward and Clinical Momentum; $67 Price Target !!! 91% UPSIDE here very low float volume is the we need to corss 44 run to 56$ my target here 84$ ! LONG and STRONG $VTVT watch $QBTS $AKTX $RGTI $DELL https://www.tipranks.com/news/ratings/vtv-therapeutics-buy-rating-reiterated-on-favorable-risk-reward-and-clinical-momentum-67-price-target-unchanged-ratings-news
0 · Reply
GDS_investing
GDS_investing May. 22 at 12:21 PM
$VTVT vTv Therapeutics: Buy Rating Reiterated on Favorable Risk-Reward and Clinical Momentum; $67 Price Target !!! 91% UPSIDE here https://www.tipranks.com/news/ratings/vtv-therapeutics-buy-rating-reiterated-on-favorable-risk-reward-and-clinical-momentum-67-price-target-unchanged-ratings-news
0 · Reply
dcajic2
dcajic2 May. 20 at 8:43 PM
$VTVT any word on investor conference went. Don’t see a presser. Short should work out just fine
0 · Reply
GDS_investing
GDS_investing May. 20 at 4:31 PM
$VTVT today long
0 · Reply
dcajic2
dcajic2 May. 19 at 4:17 PM
$VTVT Investor conference today. It’s not like VTVT will provide any news. They never ever do. Good at posting they are going but never ever tell people how it went. Still just a short
0 · Reply
GDS_investing
GDS_investing May. 19 at 2:06 PM
$VTVT Today and tomorrow vTv Therapeutics to Participate in Upcoming May Investor Conferences LONG and STRONG $VTVT
0 · Reply
dcajic2
dcajic2 May. 18 at 5:37 PM
$VTVT seem like another short would be the winner. No real data expected until the second half of the year and it could be not as good as investors were hoping.
0 · Reply
km1663
km1663 May. 15 at 5:53 PM
$VTVT Looks like a cup-n-handle on the 1 month chart
1 · Reply
GDS_investing
GDS_investing May. 15 at 1:47 PM
$VTVT red to green mode long
0 · Reply
dcajic2
dcajic2 May. 15 at 1:46 PM
$VTVT short likely will work out again. Stock may do well in the future. Hard really to know since this company rarely shares anything. My guess no news coming for a few months likely will retreat closer to $30.
0 · Reply